AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update

Author's Avatar
May 11, 2023

AVROBIO%2C+Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.